Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Forodesine · BCX-1777, NSC-717904

Small molecule · Inhibitor of purine nucleotide phosphorylase (PNP) · developed by BioCryst Pharmaceuticals

Phase 1/2 Most advanced trial (none active)

BCRX Developer

2 Registered trials

What is Forodesine?

Forodesine is a synthetic transition-state analogue that binds and inhibits purine nucleotide phosphorylase (PNP). Inhibition leads to accumulation of deoxyguanosine triphosphate, blocking DNA synthesis and selectively causing apoptosis in stimulated or malignant T-lymphocytes. It has been studied in lymphoma and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BCX-1777, NSC-717904
Drug type: Small molecule
Targets: purine nucleotide phosphorylase (PNP)
Mechanism: Inhibitor of purine nucleotide phosphorylase (PNP)
Pathways: deoxyguanosine triphosphate accumulation, ribonucleoside diphosphate reductase inhibition, DNA synthesis inhibition, apoptosis of stimulated or malignant T-lymphocytes
Therapy area: Oncology
Developer: BioCryst Pharmaceuticals (BCRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 426X066ELK

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00289549	Phase 2	Leukemia, Lymphocytic, Chronic	Completed	BCRX
NCT00061880	Phase 1/2	Lymphoma	Completed	BCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leukemia, Lymphocytic, ChronicLymphoma

More from BioCryst Pharmaceuticals

Berotralstat FDA approved Peramivir FDA approved Avoralstat Phase 3 BCX10013 Phase 1 BCX17725 Phase 1 Galidesivir Phase 1 Pelecopan Phase 2 Ulodesine Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BCRX page.

Follow BCRX, the company behind Forodesine

See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z